A method for preparing chondroitin oligosaccharides by enzymatic method and chondroitin oligosaccharide composition
By recombinant Shandachimide Hyaluronic Acid Hyaluronate Hyaluronate Hydrolyzed polymer chondroitin, high-purity chondroitin oligosan was prepared, which solved the problem of lack of effective preparation methods in the prior art and realized that chondroitin oligosan was more common. A wide range of applications.
Patent Information
- Application Number
- CN202111632894.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-28
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-12-28
AI Technical Summary
The prior art lacks effective methods for preparing chondroitin oligosan by enzymatic methods, resulting in limited application in the fields of food health care, cosmetics and clinical medicine.
Recombinant Shandachimide Hyaluronic Acid Hyaluronic Acid Hyaluronate Hyaluronate Hydrolytic enzymes were used to hydrolyze the polymer chondroitin oligosan into low-molecular chondroitin oligosan, and the impurities were removed by ultrafiltration and nanofiltration to prepare high-purity chondroitin oligosan.
The prepared chondroitin oligosan has the effects of preventing dryness, dry repair, pro-angiogenesis, antioxidant, anti-inflammatory and promoting collagen production. It is suitable for skin care products, health products, oligosaccharide drugs and other fields.
Smart Images

Figure GDA0003493955290000111 
Figure GDA0003493955290000121 
Figure GDA0003493955290000122
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of bioengineering, and in particular relates to a method for preparing chondroitin oligosaccharides by an enzymatic method and a chondroitin oligosaccharide composition. Background Art
[0002] Chondroitin sulfate is a type of glycosaminoglycan formed by alternating β1-3 and β1-4 glycosidic bonds between D-glucuronic acid and N-acetylgalactosamine and modified by sulfate at specific sites. The unsulfated polysaccharide skeleton of this glycosaminoglycan is called chondroitin. Currently, there is limited knowledge about the properties of chondroitin and its direct applications.
[0003] Chondroitin sulfate has a series of mature applications. For example, as a supplement for the treatment of joint diseases, adding it to health products can improve joint problems; adding it to cosmetics has a certain moisturizing effect; and its anti-tumor and other physiological activities have gradually come into the sight of researchers.
[0004] Chondroitin sulfate is mainly extracted from animal tissues, and the raw materials have potential safety hazards, and animal-derived products are not suitable for some special groups to accept. With the development of synthetic biology, the method of producing chondroitin by constructing microbial engineering bacteria that synthesize chondroitin (CN 108841771B, CN 109486734A), and then synthesizing chondroitin sulfate by adding sulfate groups through enzymatic or chemical modification has become a reality, thereby facilitating the large-scale production of chondroitin sulfate. This method is safer, more environmentally friendly, and has a high product acceptance, and has great application prospects.
[0005] Chondroitin and hyaluronic acid have highly similar structures. Hyaluronic acid is a macromolecular viscous polysaccharide composed of D-glucuronic acid and N-acetylglucosamine as repeating disaccharide units, connected alternately by β (1-3) and β (1-4) glycosidic bonds. Among them, glucose and galactose are isomers of each other. Therefore, chondroitin and hyaluronic acid have highly similar structures and should also have similar properties.
[0006] Literature research shows that the biological activity of hyaluronic acid depends on its molecular weight. High molecular weight hyaluronic acid can be used in the cosmetics industry, ophthalmic surgery viscoelastics and intra-articular injection therapy due to its good viscoelasticity, moisturizing, anti-inflammatory and lubricating properties. Hyaluronic acid oligosaccharides have the functions of inhibiting tumor spread, promoting wound healing, promoting bone and angiogenesis, and immunomodulation, and are easy to penetrate into the dermis, and are activators of immune cells and cytokines. Therefore, chondroitin oligosaccharides, which have a similar structure to hyaluronic acid oligosaccharides, also have broad application prospects in food health care, cosmetics and clinical medicine. However, there is currently a lack of preparation methods and efficacy research on chondroitin oligosaccharides. Summary of the invention
[0007] In view of the problems existing in the prior art, the present invention provides a method for preparing chondroitin oligosaccharides by enzymatic method and a chondroitin oligosaccharide composition.
[0008] Specifically, the present invention relates to the following aspects:
[0009] 1. A method for preparing chondroitin oligosaccharides by enzymatic method, characterized in that the method comprises the following steps:
[0010] Add hyaluronidase to the chondroitin solution for reaction.
[0011] The reaction solution is free of impurities to obtain chondroitin oligosaccharides.
[0012] The nucleotide sequence of the hyaluronidase is shown as SEQ ID NO.3.
[0013] 2. The method according to item 1, characterized in that, in the reaction system consisting of the hyaluronidase and the chondroitin solution, the concentration of chondroitin is 5-20 g / L, and preferably, the weight average molecular weight of the chondroitin is 2-3×10 5 Da.
[0014] 3. The method according to item 1, characterized in that in the reaction system consisting of the hyaluronidase and the chondroitin solution, the concentration of the hyaluronidase is 2×10 3 -1×10 5 U / mL, preferably, the ratio of the hyaluronidase to the chondroitin is 1000-3000 U / mg.
[0015] 4. The method according to item 1 is characterized in that the reaction temperature is 20-65°C and the reaction time is 0.5-8h.
[0016] 5. The method according to item 1 is characterized in that the impurities in the reaction solution are removed by ultrafiltration and nanofiltration, preferably using organic membranes with a molecular weight cutoff of 2-3 kDa and a molecular weight cutoff of 300-500 Da to remove high molecular weight impurities and low molecular weight impurities.
[0017] 6. The method according to item 1 is characterized in that the chondroitin oligosaccharide includes chondroitin tetrasaccharide, chondroitin hexasaccharide, chondroitin octasaccharide and chondroitin decasaccharide, and preferably the molecular weight of the chondroitin oligosaccharide is less than 2000Da.
[0018] 7. A chondroitin oligosaccharide composition, characterized in that the chondroitin oligosaccharide composition comprises chondroitin tetrasaccharide, chondroitin hexasaccharide, chondroitin octasaccharide and chondroitin decasaccharide.
[0019] 8. The composition according to item 7, characterized in that the molecular weight of the chondroitin oligosaccharide is less than 2000Da.
[0020] 9. The composition according to item 4, characterized in that the chondroitin oligosaccharide is prepared by the method described in any one of items 1-6.
[0021] 10. Use of the composition described in any one of items 7-9 for any one or more of preventing dryness, repairing dryness, promoting angiogenesis, protecting or repairing ultraviolet damage, anti-inflammation, and promoting collagen production.
[0022] The invention utilizes the developed recombinant mountain giant ant hyaluronan hydrolase to hydrolyze high molecular weight chondroitin into low molecular weight chondroitin oligosaccharides. The high molecular weight impurities and small molecular weight salts are further removed by ultrafiltration and nanofiltration treatment, and the powdered chondroitin product prepared by spray drying has a purity of about 95%. The prepared high-purity chondroitin oligosaccharides have anti-drying and dryness repairing effects, angiogenesis promoting effects, and anti-oxidation, anti-inflammatory, and collagen production promoting effects, and have potential and wide application value in the fields of skin care products, health care products, and oligosaccharide drug screening. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 This is the total ion current peak diagram of the LCMS-IT-TOF mass spectrum of the high molecular weight chondroitin hydrolysis product.
[0024] Figure 2 This is the ion intensity diagram of the captured chondroitin tetrasaccharide (CH4).
[0025] Figure 3 This is the ion intensity diagram of the captured chondroitin hexasaccharide (CH6).
[0026] Figure 4 The ion intensity diagram of the captured chondroitin octasaccharide (CH8).
[0027] Figure 5 The ion intensity diagram of the captured chondroitin decasaccharide (CH10). DETAILED DESCRIPTION
[0028] The present invention is further described below in conjunction with examples. It should be understood that the examples are only used to further illustrate and explain the present invention, and are not intended to limit the present invention.
[0029] Unless otherwise defined, the technical and scientific terms in this specification are the same as those commonly understood by those skilled in the art. Although similar or identical methods and materials as described herein can be used in experiments or practical applications, materials and methods are described herein below. In the event of a conflict, the present specification including the definitions therein shall prevail. In addition, materials, methods and examples are for illustration only and are not restrictive. The present invention is further described below in conjunction with specific embodiments, but is not intended to limit the scope of the present invention.
[0030] Chondroitin oligosaccharide refers to a low molecular weight polysaccharide compound formed by the polymerization of D-glucuronic acid and N-acetylgalactosamine through 2-10 glycosidic bonds. The molecular weight ranges from hundreds to thousands of Daltons, and the molecular weight generally does not exceed 5000Da.
[0031] Hyaluronidase is a type of glycosidase that can degrade hyaluronic acid and some glycosaminoglycans. According to the differences in the source, catalytic mechanism and substrate specificity of hyaluronidase, it can be divided into three categories: the first category is hyaluronic acid lyase from microorganisms. This type of hyaluronidase (EC 4.2.2.1) cleaves the β-1,4 glycosidic bond of hyaluronic acid through a β racemization reaction, and the reducing end of the generated oligosaccharide is an unsaturated N-acetylglucosamine structure; the second type of representative hyaluronidase (EC3.2.1.36) is mainly derived from the salivary glands of leeches, and is an endo-β-glucuronidase that can hydrolyze the β-1,3 glycosidic bond of hyaluronic acid, and the reducing end of the generated oligosaccharide is a glucuronic acid structure; the third type of hyaluronidase is endo-β-N-acetylglucosamine sidase (EC 3.2.1.35), which is mainly derived from the testicles of mammals and animal venom, and can hydrolyze hyaluronic acid, chondroitin sulfate and chondroitin, etc.
[0032] Since the third type of hyaluronidase is mainly derived from the testicles of mammals and the venom of animals, the extraction process is complicated and the cost is high, thus limiting its industrial application. Moreover, the chondroitin products on the existing market usually exist as chondroitin sulfate, and chondroitin sulfate is mainly extracted from animal tissues, and the raw materials have potential safety hazards. Therefore, although chondroitin oligosaccharides have potential application value in the fields of skin care products, health products and oligosaccharide drugs, there is no method for producing chondroitin oligosaccharides using enzymatic methods.
[0033] The present invention provides a method for preparing chondroitin oligosaccharides by enzymatic method, the method comprising the following steps: adding hyaluronidase to a chondroitin solution for reaction, removing impurities from the reaction solution by ultrafiltration and nanofiltration steps to obtain chondroitin oligosaccharides, wherein the nucleotide sequence of the hyaluronidase is shown as SEQ ID NO.3.
[0034] The hyaluronidase used in the present invention is a hyaluronidase from the mountain big-toothed ant source. The hyaluronidase from the mountain big-toothed ant source belongs to the third class of hyaluronidase, which is an endo-β-N-acetylglucosaminidase, which can hydrolyze the β-1,4 glycosidic bond of hyaluronic acid, and the reducing end of the final product is N-acetylgalactosamine. In addition, this type of enzyme is wider than the second class of leech hyaluronan hydrolase substrate spectrum, and has certain catalytic activity to chondroitin, chondroitin sulfate and dermatan sulfate structures. The mountain big-toothed ant hyaluronidase can enrich the types of hyaluronic acid products, and can also have a wider range of applications except hyaluronidase catalysis.
[0035] The nucleotide sequence of the hyaluronidase of the present invention is shown in SEQ ID NO.3, and the protein sequence encoded by it is shown in SEQ ID NO.4. The nucleotide sequence shown in SEQ ID NO.3 can be used to produce hyaluronidase using Pichia pastoris. In a specific embodiment, the method of using Pichia pastoris to produce hyaluronidase includes using BMMY medium and methanol induction to ferment and produce hyaluronidase. The composition of BMMY medium is yeast extract 10g / L, peptone 20g / L, K2HPO4 3g / L, KH2PO4 11.8g / L, YNB 3.4g / L, (NH4)2SO4 10g / L, biotin 4×10 -4 g / L, methanol 10mL / L. In a preferred embodiment, the shake flask fermentation conditions are: the fermentation temperature is 25°C-30°C, 0.5%-1% (v / v) methanol is added every 24h during the fermentation process, and the expression is induced for 96h. The hyaluronidase of the present invention has a high expression level, and the activity of the hyaluronidase in the fermentation supernatant at the end of the fermentation can be as high as 67970.04U / mL.
[0036] In a specific embodiment, in the reaction system consisting of the hyaluronidase and the chondroitin solution, the initial concentration of chondroitin is 5-20g / L, for example, 5g / L, 6g / L, 7g / L, 8g / L, 9g / L, 10g / L, 11g / L, 12g / L, 13g / L, 14g / L, 15g / L, 16g / L, 17g / L, 18g / L, 19g / L, 20g / L. For example, the reaction system formed by adding hyaluronidase to the chondroitin solution is 1L, and the initial content of chondroitin is 5-20g, that is, the content when no hydrolysis occurs is 5-20g.
[0037] In a specific embodiment, the initial molecular weight of chondroitin is 2-3×10 5 Da, for example, can be 2×10 5 Da, 2.5×10 5 Da, 3×10 5 Da.
[0038] The molecular weights used in the present invention, unless otherwise specified, represent weight average molecular weights.
[0039] Hyaluronidase can be added directly in the form of a dry enzyme preparation, or can be added after being prepared into a solution, or can be directly added as a hyaluronidase ultrafiltration concentrate.
[0040] In a specific embodiment, in the reaction system consisting of the hyaluronidase and the chondroitin solution, the concentration of the hyaluronidase is 2×10 3 -1×10 5 U / mL, for example, 2×10 3 U / mL, 3×10 3 U / mL, 4×10 3 U / mL, 5×10 3 U / mL, 6×10 3 U / mL, 8×10 3 U / mL, 10 4 U / mL, 2×10 4 U / mL, 4×10 4 U / mL, 6×10 4 U / mL, 8×10 4 U / mL, 10 5 U / mL. The definition of hyaluronidase activity unit (U) is: the amount of enzyme required to release 1 μg of glucose reducing equivalent from hyaluronic acid sugar chains per hour at pH 5.5 and 38°C.
[0041] The reaction system can be at a pH condition that is conducive to the hyaluronidase reaction, such as an acidic pH. In a specific embodiment, the pH of the reaction system is 4.0-6.5, and the buffer used is an acetic acid-sodium acetate buffer with a molar concentration of 20-100 mM.
[0042] In a specific embodiment, the reaction temperature is 20-65°C and the reaction time is 0.5-8h.
[0043] By regulating the concentration of hyaluronidase, reaction temperature, reaction time and other conditions in the reaction system, oligosaccharide products with different molecular weights and dispersities can be obtained.
[0044] The present invention removes impurities from the reaction solution by ultrafiltration and nanofiltration. Ultrafiltration is a membrane separation technology (UItrafil-tration, referred to as UF). It can purify, separate or concentrate the solution. Ultrafiltration is between microfiltration and nanofiltration, and there is no obvious dividing line between the three. Generally speaking, the pore size of the ultrafiltration membrane is between 0.05μm-1nm, and the operating pressure is 0.1-0.5Mpa. It is mainly used to intercept and remove macromolecular substances such as suspended matter, colloids, particles, bacteria and viruses in water. Ultrafiltration membranes can be divided into organic membranes and inorganic membranes according to the membrane material. According to the appearance of the membrane, it can be divided into: flat type, tubular type, capillary type, hollow fiber and porous type. At present, household ultrafiltration water purifiers are mostly hollow membranes.
[0045] Nanofiltration (NF) is a pressure-driven membrane separation process between reverse osmosis and ultrafiltration. The pore size of the nanofiltration membrane is in the range of several nanometers. Nanofiltration (NF) is used to separate substances with relatively small molecular weight, such as inorganic salts or small molecular organic substances such as glucose and sucrose, from solvents. Nanofiltration, also known as low-pressure reverse osmosis, is an emerging field of membrane separation technology. Its separation performance is between reverse osmosis and ultrafiltration, allowing some inorganic salts and certain solvents to pass through the membrane, thereby achieving the separation effect.
[0046] In a specific embodiment, the reaction solution is first separated on an organic membrane separator using an organic membrane with a molecular weight cutoff of 2-3 kDa to retain high molecular impurities and pass low molecular weight chondroitin oligosaccharides, and then separated using an organic membrane with a molecular weight cutoff of 300-500 Da to retain low molecular weight chondroitin oligosaccharides while removing small molecular weight salts.
[0047] The retention molecule described in the present invention is the retention performance of the ultrafiltration membrane expressed by the molecular weight, also known as the cut-off molecular weight. Since it is quite difficult to directly measure the pore size of the ultrafiltration membrane or the nanofiltration membrane, a spherical substance with a known molecular weight is used for measurement. If the retention rate of the membrane for the retained substance is greater than 90%, the retention performance of the membrane is expressed by the molecular weight of the retained substance, which is called the membrane's retention molecular weight. For example, a membrane with a molecular weight cut-off of 2kDa can retain substances with a molecular weight greater than 2kDa, while allowing substances with a molecular weight less than 2kDa to pass through.
[0048] The method of the present invention may further include spray drying the nanofiltration retentate to prepare a solid powder.
[0049] In a specific embodiment, the chondroitin oligosaccharide includes chondroitin tetrasaccharide, chondroitin hexasaccharide, chondroitin octasaccharide and chondroitin decasaccharide, and preferably the weight average molecular weight of the chondroitin oligosaccharide is less than 2000 Da.
[0050] The molecular weight of the sample is determined by a multi-angle laser light scattering instrument-high performance liquid chromatography system (GPC-MALLS). The chromatographic column: TSKgel GMPWXL liquid chromatography column, 7.8mm x 300mm, 13μm; column temperature: 35°C; mobile phase: 0.2mol / L sodium chloride solution (containing 0.2% ProClin200); flow rate: 0.6mL / min; the laser wavelength of the multi-angle laser scattering instrument is 658nm. When loading, the concentration of the test sample should be 0.05mg / mL and filtered through a 0.22μm filter membrane. The weight average molecular weight and molecular weight distribution of the test sample are calculated using special software.
[0051] Among them, the detection of chondroitin oligosaccharide products adopts the hydrolysis product structure analysis method. The specific conditions are: the product analysis is carried out using Shimadzu's LCMS-IT-TOF liquid mass spectrometer, and the mass spectrometer selects the negative ion detection mode. The mobile phase selection is: the acetonitrile concentration is linearly increased to 12% in 21 minutes and reduced to 0 in 22 minutes.
[0052] Among them, the specific method for determining the chondroitin content is: add 1mL of appropriately diluted sample to a glass tube containing 5mL of borax sulfuric acid (4.77g of borax dissolved in 500mL of concentrated H2SO4), mix well, boil in a boiling water bath for 15min, and cool to room temperature. Add 20μL of carbazole reagent (0.125g of carbazole dissolved in 100mL of anhydrous ethanol), mix well and boil for 15min. Determine the absorbance value at a wavelength of 530nm. Perform the same reaction with D-glucuronic acid standards of different concentrations (10, 20, 30, 40, 50μg / mL) to draw a standard curve. Standard curve equation: y=0.0149x-0.0239, R2=0.9991 (x, glucuronic acid content in the sample (μg / mL); y, absorbance A530). The calculation formula of chondroitin production is: chondroitin content (g / L) = (concentration measured by standard curve × dilution factor × 2.067) / 1000.
[0053] The present invention also provides a chondroitin oligosaccharide composition, which comprises chondroitin tetrasaccharide, chondroitin hexasaccharide, chondroitin octasaccharide and chondroitin decasaccharide.
[0054] In a specific embodiment, the weight average molecular weight of the chondroitin oligosaccharide is less than or equal to 2000 Da.
[0055] In a specific embodiment, the chondroitin oligosaccharide is prepared by the above method.
[0056] The present invention also provides the use of the above chondroitin oligosaccharide composition in any one or more of preventing dryness, repairing dryness, promoting angiogenesis, protecting or repairing ultraviolet damage, anti-inflammation, and promoting collagen production.
[0057] Specifically, the chondroitin oligosaccharide composition has the effects of preventing desiccation and repairing desiccation within a concentration range of 0.5-2.0 mg / mL.
[0058] The chondroitin oligosaccharide composition has a significant effect of promoting angiogenesis within a concentration range of 0.25 mg / mL-1 mg / mL.
[0059] The chondroitin oligosaccharide composition can inhibit ultraviolet damage and has a clearing effect on the generation of intracellular ROS induced by ultraviolet rays.
[0060] The chondroitin oligosaccharide composition can inhibit the secretion of TNF-α in cells induced by LPS and has a certain anti-inflammatory effect.
[0061] The chondroitin oligosaccharide promotes the production of procollagen I alpha 1, thereby promoting the production of collagen.
[0062] The present invention utilizes recombinant mountain giant ant hyaluronan hydrolase to hydrolyze high-molecular chondroitin into low-molecular chondroitin oligosaccharides. The obtained chondroitin oligosaccharide composition has the effects of preventing dryness, repairing dryness, promoting angiogenesis, protecting or repairing ultraviolet damage, anti-inflammatory, and promoting collagen production. Compared with the hyaluronic acid oligosaccharide composition, these effects are equivalent to or more significant, so it has potential and wide application value in the fields of skin care products, health care products, etc.
[0063] Example
[0064] Example 1 Hyaluronidase gene (ΔN24HYAL_OM opt )Construction of expression system
[0065] Chemical synthesis of the codon-optimized hyaluronan hydrolase gene sequence (HYAL_OM opt ), the sequence of which is shown in SEQ ID NO.1, and the amino acid sequence encoded by it is shown in SEQ ID NO.2. opt The recombinant expression vector pPIC9K-HYAL_OM was cloned into the EcoRI and NotI restriction sites of the Pichia pastoris expression vector pPIC9K to obtain the recombinant expression vector pPIC9K-HYAL_OM opt . Recombinant expression plasmid pPIC9K-HYAL_OM opt After linearization with SalI fast-cutting enzyme, the gene was electroporated into P. pastoris GS115 expression host cells. The recombinant transformants were screened by geneticin G418 to obtain high-copy recombinant P. pastoris GS115 / pPIC9K-HYAL_OM opt .
[0066] pPIC9K-HYAL_OM opt The recombinant expression vector was used as a template to design primers and cut off the hyaluronan hydrolase gene sequence (HYAL_OM opt ) N-terminal signal peptide sequence, and obtain the high expression hyaluronan hydrolase gene (ΔN24HYAL_OM opt ) fragment, the sequence of which is shown in SEQ ID NO.3, and the amino acid sequence encoded by it is shown in SEQ ID NO.4.
[0067] The primer sequences are as follows:
[0068] Upstream primer F: 5'-CCGGAATTCATGAAGACACTACGCGGCTC-3' (SEQ ID NO. 5);
[0069] Downstream primer R: 5'-ATTTGCGGCCGCTCAATGATGATGATGGTGGTGATGAAGGGTGAACTTCTT-3' (SEQ ID NO. 6);
[0070] It should be noted that the GAATTC sequence in the upstream primer is an introduced EcoRI restriction enzyme site, the GCGGCCGC sequence in the downstream primer is an introduced NotI restriction enzyme site, and the reverse complementary sequence of the ATGATGATGATGGTGGTG sequence in the downstream primer encodes a 6×His-tag tag.
[0071] The amplified genetic engineering hyaluronan hydrolase gene fragment was double-digested with EcoRI and NotI, cloned into the linear expression vector pPIC9K treated with the same enzymes, and transformed into E.coil TOP10 to obtain the recombinant expression plasmid pPIC9K-ΔN24HYAL_OM while ensuring that the reading frame was not shifted. opt The recombinant sequence was correct after DNA sequencing. The recombinant plasmid was linearized with restriction endonuclease SalI and then electroporated into P. pastoris GS115 cells. The recombinant transformants were screened with geneticin G418 to obtain the recombinant bacteria P. pastoris GS115 / pPIC9K-ΔN24HYAL_OM with high copy number of hyaluronan hydrolase gene. opt .
[0072] Example 2 Expression of Hyaluronidase
[0073] The obtained recombinant engineering bacteria P. pastoris GS115 / pPIC9K-HYAL_OM opt and P.pastorisGS115 / pPIC9K-ΔN24HYAL_OM opt The fermentation was carried out in shake flasks. The fermentation steps were as follows: a single clone was picked and inoculated into 40 mL of YPD medium (10 g / L yeast extract, 20 g / L peptone, 20 g / L glucose), and cultured at 30°C and 200 rpm for 24 h. A 10% inoculation volume was transferred to 40 mL of the initial expression medium BMGY (10 g / L yeast extract, 20 g / L peptone, 3 g / L K2HPO4, 11.8 g / L KH2PO4, 3.4 g / L YNB, 10 g / L (NH4)2SO4, 4 × 10 -4g / L, glycerol 10mL / L), and cultured at 30℃, 200rpm for 24h. The cells were collected by centrifugation, washed with physiological saline, and then replaced with 40mL induced expression medium BMMY (yeast extract 10g / L, peptone 20g / L, K2HPO4 3g / L, KH2PO4 11.8g / L, YNB 3.4g / L, (NH4)2SO4 10g / L, biotin 4×10 -4 g / L, methanol 10mL / L), cultured at 30°C and 200rpm, pure methanol was added to the culture medium every 24h to a final concentration of 1.0% (v / v) to induce expression, and the induced expression was continued for 96h.
[0074] At the end of fermentation, the DNS method was used to determine the reducing sugar equivalent produced by hydrolyzing hyaluronic acid, and analytical pure glucose was used as the standard curve to calculate the hyaluronidase activity. The reaction system was 1 mL: an appropriate amount of fermentation supernatant (the blank was an equal volume of fermentation supernatant after boiling and inactivation) was added to 800 μL of 2 mg / mL hyaluronic acid substrate solution, and 1 mL was added with 50 mM citric acid buffer (pH 5.5), and incubated at 38°C for 15 minutes. After the reaction was completed, it was immediately placed in a boiling water bath for 2 minutes to inactivate the enzyme to terminate the reaction. The treated 1 mL reaction solution was added to 2 mL DNS (sodium potassium tartrate tetrahydrate 248 g / L, 3,5-dinitrosalicylic acid 6.3 g / L, 2M NaOH 250 mL / L, phenol 5.136 g / L, sodium sulfite 5 g / L) solution, oscillated and mixed, and boiled in a boiling water bath for 10 min together with the glucose standard curve sample; after cooling to room temperature in an ice water bath, 7 mL of deionized water was added, oscillated and mixed, and the absorbance was measured at 540 nm and converted to the amount of reducing sugar produced by the reaction. The crude enzyme activity of the recombinant engineered bacteria fermentation supernatant was calculated based on the glucose standard curve.
[0075] The results showed that the recombinant strain P. pastoris GS115 / pPIC9K-HYAL_OM opt The fermentation supernatant enzyme activity of the recombinant strain P. pastoris GS115 / pPIC9K-ΔN24HYAL_OM opt The fermentation supernatant enzyme activity reached 67748.32U / mL. This indicates that the hyaluronan hydrolase gene (ΔN24HYAL_OM opt ) relative to the codon-optimized hyaluronan hydrolase gene (HYAL_OM opt ), the expression capacity increased by nearly 20 times, making it possible to use enzymatic methods to industrially produce oligosaccharides.
[0076] Example 3 Production of Hyaluronidase
[0077] The recombinant strain P. pastoris GS115 / pPIC9K-ΔN24HYAL_OM opt A 5-L fermenter was used for high-density culture. A single colony on the YPD plate was inoculated into 40 mL YPD liquid medium (10 g / L yeast extract, 20 g / L peptone, 20 g / L glucose), cultured at 30°C and 220 rpm for 24 h, and the culture solution was inoculated into 200 mL BMGY medium (10 g / L yeast extract, 20 g / L peptone, 3 g / L K2HPO4, 11.8 g / L KH2PO4, 3.4 g / L YNB, 10 g / L (NH4)2SO4, 4 × 10 -4 g / L, glycerol 10g / L), cultured at 30℃220rpm for 24h; 200mL seed solution cultured for 24h was inoculated into 2LBSM fermentation medium (glycerol 40g / L, K2SO4 18g / L, KOH 4.13g / L, 85% H3PO4 26.7mL / L, CaSO4·2H2O0.93g / L, MgSO4·7H2O 14.9g / L, 4.4mL / L filtered sterilized PTM1; PTM1 formula: CuSO4·5H2O 6g / L, KI0.09g / L, MnSO4·H2O 3g / L, H3BO3 0.02g / L, MoNa2O4·2H2O 0.2g / L, CoCl2·6H2O 0.92g / L, ZnCl2 20g / L, FeSO4·7H2O 65g / L, biotin 0.2g / L, H2SO4 5.0mL) in a 5-L fermenter. The initial fermentation parameters were set at 30°C, pH 5.5, ventilation volume 2.0vvm and rotation speed 500rpm; during the fermentation process, the pH was controlled at 5.5 by automatically adding ammonia water; after the glycerol in the BSM medium was exhausted, the batch feeding stage was entered, and 50% (v / v) glycerol (containing 12mL / LPTM1) was added in an exponential manner, and the rotation speed was set to couple with dissolved oxygen DO, and the feeding rate was 13.5, 16.2, 19.2, 22.8, 27.2 and 32.4mL / h / L in the first 6h, and the feeding rate for the subsequent 6h was set to 30mL / h / L; after the feeding was completed, the starvation culture stage was entered, and the starvation culture was carried out for 2-3h until the residual glycerol was exhausted; the methanol induction stage was entered, and pure methanol containing 12mL / LPTM1 was added and the final concentration was maintained at 1.8% (v / v), and the fermentation temperature was adjusted to 25°C, the rotation speed was increased to 1000rpm, and the induction was 88h, and the methanol flow rate and the final methanol concentration in the culture medium were controlled online in real time by the methanol detector.
[0078] After the fermentation is completed, centrifuge at 9000rpm and 4℃ for 15min, collect the centrifugal supernatant, filter through a 0.22um filter membrane to remove particulate impurities, and the obtained filtrate is subjected to low-temperature ultrafiltration. The molecular weight cutoff of the organic ultrafiltration membrane is 10kDa. The product enzyme molecules are in the retained liquid, and small molecular impurities such as high-valent salt ions are discharged with the permeate. The system is cooled by cooling circulating water during the ultrafiltration process. The conductivity change of the retained liquid is tracked and detected during the ultrafiltration process. When the conductivity of the retained concentrated liquid no longer changes and the flow rate of the permeate decreases, add an equal volume of purified water to dilute it to facilitate permeation; dilute it repeatedly several times. When the conductivity of the retained concentrated liquid is lower than 500us / cm, stop ultrafiltration, collect the retained enzyme liquid, and store it in a refrigerator.
[0079] The activity of the purified hyaluronidase was 2.8×10 5 U / mL.
[0080] Example 4 Preparation of Chondroitin Oligosaccharides
[0081] Chondroitin (obtained according to the method described in patent publication CN106497845B) was hydrolyzed with the hyaluronidase ultrafiltration concentrate prepared in Example 3 to prepare chondroitin oligosaccharides.
[0082] The starting molecular weight of chondroitin used is 1-3×10 5 Da. Add 1.8L of 50mM acetic acid-sodium acetate buffer (pH 5.5) to a 3L reaction tank, add 20g of chondroitin, 200mL of hyaluronidase ultrafiltration concentrate (enzyme activity 2.8×10 5 U / mL), the hydrolysis temperature was set to 37°C, and the rotation speed was set to 150rpm. After 4h of reaction, the temperature was adjusted to 60°C and kept warm for 60min to inactivate the enzyme. The inactivated liquid was transferred to a cooking tank, 0.5% (w / v) activated carbon was added, and the mixture was stirred at 60°C and 150rpm for 60min. The activated carbon was first removed by filtering with a filter paper, and then filtered with a 0.22μm nylon filter membrane.
[0083] The filtered clear liquid is first treated with a 2kDa organic ultrafiltration membrane to separate high molecular impurities and low molecular chondroitin oligosaccharides. The initial conductivity of the feed liquid is 3.0-5.0ms / cm. The conductivity changes of the retentate and permeate during the ultrafiltration process are continuously monitored. When the conductivity of the retentate tends to be stable and the flow rate of the permeate decreases, add pure water to dilute it to facilitate permeation. Repeat the dilution several times until the conductivity of the retentate is around 1ms / cm and the conductivity of the permeate is below 100us / cm. Stop the ultrafiltration process and collect the permeate. Replace the 500Da nanofiltration membrane.
[0084] The ultrafiltration permeate is then passed through a 500Da organic nanofiltration membrane to intercept low molecular weight oligosaccharides and pass small molecular weight salts. The feed liquid is first concentrated until the conductivity of the concentrated liquid reaches 1.0-1.2ms / cm, and when the permeate flow rate decreases, pure water is added to dilute it. The operation is repeated several times until the permeate conductivity is below 50us / cm, and the nanofiltration process is stopped. The nanofiltration retentate is collected.
[0085] The nanofiltration retentate was spray dried to prepare a solid powder. The spray drying parameters were set as follows: inlet temperature 170°C, air suction 98%, and feed pump flow rate 30 mL / min. The component analysis of the obtained chondroitin oligosaccharide sample is shown in Figure (1-5), and the quality indicators are shown in Table 1.
[0086] Table 1 Quality indexes of chondroitin oligosaccharide samples
[0087]
[0088] Among them, the mass spectrometry results are as follows Figure 1 As shown in Table 2, the sample taken after the reaction was pretreated and then analyzed by LCMS-IT-TOF. The negative ion types and molecular weights of chondroitin oligosaccharides after electrospray ionization (ESI) are shown in Table 2. The mass spectrometry detection results are shown in Table 2. Figure 1 As shown, the mass peaks at 3.75min and 4.05min on the mass spectrometer total ion current peak diagram are in negative ion mode [MH] - was 775.22, identified as chondroitin tetrasaccharide ( Figure 2 ); The mass peaks at 5.15min and 5.40min on the mass spectrometer total ion current peak graph are in negative ion mode [MH] - 1154.33, [MH] 2- was 576.66, identified as chondroitin hexasaccharide ( Figure 3 ); The mass peak at 6.30min on the mass spectrometer total ion current peak graph is in negative ion mode [MH] 2- was 766.21, identified as chondroitin octasaccharide ( Figure 4 ); The mass peak at 6.80min on the mass spectrometer total ion current peak diagram is in negative ion mode [MH] 2- was 955.77, and was identified as chondroitin decasaccharide ( Figure 5 ).
[0089] Table 2 ESI anion types and molecular weights of chondroitin oligosaccharides
[0090]
[0091] Chondroitin is hydrolyzed by hyaluronidase to generate a mixture of tetrasaccharides, hexasaccharides, octasaccharides and decasaccharides. The components of chondroitin oligosaccharides have different molecular weights and can be separated by high-performance liquid phase separation of gel filtration columns and detected by broad-spectrum absorption. GE gel column model: SuperdexTM75 Increase 10 / 300GL. Mobile phase: 5mM ammonium acetate, flow rate: 0.6mL / min. Time: 65min, detection wavelength 200nm. The proportion of each oligosaccharide component can be calculated by the integral peak area normalization method. As shown in Table 3, the proportion of chondroitin tetrasaccharide in the main components is about 22.53%, the proportion of chondroitin hexasaccharide is about 29.35%, the proportion of chondroitin octasaccharide is about 21.83%, and the proportion of chondroitin decasaccharide is about 11.24%.
[0092] Table 3 Proportion of chondroitin oligosaccharide components
[0093]
[0094] Example 5 Preparation of hyaluronic acid oligosaccharides
[0095] The hyaluronic acid was hydrolyzed with the hyaluronidase ultrafiltration concentrate prepared in Example 3 to prepare hyaluronic acid oligosaccharides.
[0096] Add the above-mentioned hyaluronidase ultrafiltration concentrate with a final concentration of 6000U / mL to a 40g / L sodium hyaluronate solution (molecular weight of 1.0-1.3 million Da). React the reaction system at 37°C, 300rpm for 8h. After the reaction is completed, adjust the temperature to 60°C and keep it warm for 60min to inactivate the enzyme. Transfer the inactivated liquid to a cooking tank, add 0.5% (w / v) activated carbon, and stir at 60°C, 150rpm for 60min. First filter with filter paper to remove the activated carbon, and then filter with a 0.22μm nylon filter membrane.
[0097] The filtered clear liquid is first treated with a 2kDa organic ultrafiltration membrane, and the conductivity changes of the retentate and permeate are continuously monitored during the ultrafiltration process. When the conductivity of the retentate tends to be stable and the flow rate of the permeate decreases, pure water is added to dilute it to facilitate permeation. Repeat the dilution several times until the conductivity of the retentate is around 1ms / cm and the conductivity of the permeate is below 100us / cm, stop the ultrafiltration process, and collect the permeate. Replace the 500Da nanofiltration membrane.
[0098] The ultrafiltration permeate is then passed through a 500Da organic nanofiltration membrane to intercept low molecular weight oligosaccharides and pass small molecular weight salts. The feed liquid is first concentrated until the conductivity of the concentrated liquid reaches 1.0-1.2ms / cm, and when the permeate flow rate decreases, pure water is added to dilute it. The operation is repeated several times until the permeate conductivity is below 50us / cm, and the nanofiltration process is stopped. The nanofiltration retentate is collected.
[0099] The nanofiltration retentate was spray dried to prepare a solid powder. Spray drying parameter settings: inlet temperature 170°C, air suction 98%, feed pump flow rate 30mL / min. The obtained hyaluronic acid oligosaccharide sample. Experimental Example Efficacy experiment of chondroitin oligosaccharide
[0100] Chondroitin and hyaluronic acid have highly similar structures, and it is speculated that they should also have similar properties. Literature research shows that the biological activity of hyaluronic acid depends on its molecular weight. Hyaluronic acid oligosaccharides have the functions of inhibiting tumor spread, promoting wound healing, promoting bone and angiogenesis, and immunomodulation, and are easy to penetrate into the dermis as an activator of immune cells and cytokines. Hyaluronic acid oligosaccharide raw materials are currently widely used in various types of skin care products, health care products and other products.
[0101] The efficacy study of chondroitin oligosaccharides mainly examines the cytotoxicity, moisture retention, angiogenesis promotion, anti-inflammatory, anti-aging and other effects of chondroitin oligosaccharides and other samples. The chondroitin oligosaccharides prepared in Example 4 were compared with hyaluronic acid oligosaccharides (molecular weight less than 2000Da) to better illustrate the efficacy properties of chondroitin oligosaccharides.
[0102] 1. Cytotoxicity Experiment Evaluation
[0103] The cytotoxicity test method refers to: GB / T16886.5-2017 Biological evaluation of medical devices Part 5: In vitro cytotoxicity test (ISO 10993-5:2009, IDT) and "People's Republic of China Entry-Exit Inspection and Quarantine Industry Standard" SNT2328-2009 Keratinocyte test for acute toxicity of cosmetics.
[0104] HaCaT cells in logarithmic growth phase were taken and 1×10 5 The cells were inoculated in a 96-well plate at a density of cells / mL, with 100 μL per well. The culture system was DMEM high-glucose culture medium supplemented with 10% fetal bovine serum. The inoculated cells were placed in a carbon dioxide incubator at 37°C and 5% CO2 for routine culture for 24 hours.
[0105] The sample solution was prepared with serum-free culture medium, and sterilized by filtration through a 0.22 μm filter membrane before use.
[0106] After routine culture for 24 h, the old culture medium was discarded, and the experimental group was replaced with 100 μL sample, and the control group (control) was added with an equal amount of serum-free culture medium, with 6 parallel wells at each level.
[0107] After continuing to culture for 24 hours, the CCK-8 method was used to detect the relative cell proliferation rate. The culture medium was discarded, and 100 μL of CCK-8 diluted 10 times with serum-free culture medium was added to each well. The cells were placed in a cell culture incubator and continued to incubate for 2 hours. The absorbance was measured at a wavelength of 450 nm using an enzyme reader. The relative proliferation rate (RGR) is the ratio of the absorbance of the experimental group to the absorbance of the normal control group. According to the requirements of GB / T16886.5-2017, when the RGR is lower than 70%, the sample is considered to be cytotoxic. According to the standard of non-cytotoxicity, a relative proliferation rate of more than 70% is used.
[0108] The results are shown in Table 4. Chondroitin oligosaccharide has no cytotoxicity in the concentration range of 0.5 mg / mL-2.0 mg / mL. This result proves the safety of chondroitin oligosaccharide.
[0109] Table 4 Cytotoxicity of samples (RGR, %)
[0110]
[0111] 2. Sample moisturizing test
[0112] The cell drying method is to place the adherent cells in a dry environment to make them lose water, causing a certain degree of drying damage to the cells. Drugs are added before or after drying to examine their anti-desiccation or post-drying repair effects.
[0113] Prepare a glass desiccator and add 200 g of silica gel drying particles (85 degrees Celsius oven for 4 hours). The relative humidity in the desiccator is 10%. 5 HaCaT cells were seeded in a 96-well plate at a density of 100 μL / mL, and cultured at 37°C and 5% CO2 for 24 h.
[0114] In the clean bench, tilt the 96-well plate downward at a 60-degree angle, and use a 1mL syringe with the notch of the needle facing downward to suck out the culture medium in the wells. Use the wells that have not been sucked dry as a control, and seal the wells that have not been sucked dry with a sealing film. Place the wells in a dryer with the open surface and dry for a certain period of time.
[0115] After drying for a certain period of time, add drug solutions of different concentrations, 100 μL per well. For the control group, discard the old culture medium, add new serum-free culture medium, and measure the cell survival rate with CCK-8 as in 1.4.
[0116] In the anti-drying experiment, add the medicine first and then dry it.
[0117] 2.1 Sample drying and repair experiment
[0118] The results are shown in Table 5. Compared with the Control, the cell proliferation rate of the drying model group decreased by 18.87% after drying, and there was a significant difference compared with the control group, indicating that the model was successful. The data showed that chondroitin oligosaccharide had a drying repair effect in the range of 0.5mg / mL-2.0mg / mL, and the drying repair effect was best at a concentration of 0.5mg / mL. Hyaluronic acid oligosaccharide can achieve the best effect at a concentration of 2.0mg / mL, which also shows the application advantage of chondroitin oligosaccharide.
[0119] Table 5 Effects of samples on cell drying and repair (RGR, %)
[0120]
[0121] Note: ## indicates p<0.01 compared with Control; * indicates p<0.05 compared with dry model group; ** indicates p<0.01 compared with dry model group (t test).
[0122] 2.2 Sample drying protection experiment
[0123] The results are shown in Table 6. Compared with the Control, the cell proliferation rate of the drying model group decreased by 16.66% after drying, and there was a significant difference compared with the control group, indicating that the model was successfully established. Chondroitin oligosaccharide and hyaluronic acid oligosaccharide both have anti-drying effects within the effective concentration range (0.5-2.0 mg / mL).
[0124] Table 6 Effect of samples on cell drying protection (RGR, %)
[0125]
[0126] Table Notes: ## indicates p<0.01 compared with Control; * indicates p<0.05 compared with dry model group; ** indicates p<0.01 compared with dry model group (t test).
[0127] 3. Pro-angiogenic effect of samples
[0128] EA.hy926 cells in logarithmic growth phase were taken and 1×10 5 The cells were inoculated in a 96-well plate at a density of cells / mL, with 100 μL per well. The culture system was DMEM high-glucose culture medium supplemented with 10% fetal bovine serum. The inoculated cells were placed in a carbon dioxide incubator at 37°C and 5% CO2 for routine culture for 24 hours.
[0129] The sample solution was prepared with serum-free culture medium, and sterilized by filtration through a 0.22 μm filter membrane before use.
[0130] After routine culture for 24 h, the old culture medium was discarded, and the experimental group was replaced with 100 μL sample, and the control group (control) was added with an equal amount of serum-free culture medium, with 6 parallel wells at each level.
[0131] After 24 hours of continuous culture, the relative proliferation rate of cells was detected by CCK-8 method. The culture medium was discarded, and 100 μL of CCK-8 diluted 10 times with serum-free culture medium was added to each well, and the cells were placed in a cell culture incubator for another 2 hours. The absorbance was measured at a wavelength of 450 nm using an enzyme marker. The relative proliferation rate (RGR) is the ratio of the absorbance of the experimental group to that of the normal control group.
[0132] The results are shown in Table 7. Chondroitin oligosaccharide has a significant effect of promoting angiogenesis at a low concentration of 0.25 mg / mL-1 mg / mL, while hyaluronic acid oligosaccharide has a significant effect only at a relatively high concentration of 2 mg / mL.
[0133] Table 7 Effects of samples on angiogenesis (RGR, %)
[0134]
[0135] * indicates p < 0.05 compared with Control; ** indicates p < 0.01 compared with Control (t test).
[0136] 4. Evaluation of antioxidant efficacy (ROS)
[0137] UVA+UVB was used to damage human epidermal keratinocytes HaCaT, simulating the damage caused by sunlight to the epidermis and stimulating the production of reactive oxygen free radicals (ROS). The cells were contacted with samples before and after irradiation, and the ROS in the cells were labeled with the fluorescent probe DCFH-DA. The content of intracellular ROS was detected by flow cytometry to examine whether the samples had the ability to inhibit the production of ROS or eliminate ROS.
[0138] The DCFH-DA probe can freely pass through the cell membrane. After entering the cell, it is hydrolyzed by the esterase in the cell to produce DCFH. DCFH cannot pass through the cell membrane. Therefore, the probe is loaded into the cell and will not be lost. The ROS in the cell can oxidize the non-fluorescent DCFH to produce fluorescent DCF. The level of reactive oxygen in the cell is reflected by detecting the average fluorescence intensity of DCF.
[0139] The sample solutions were prepared with serum-free DMEM culture medium, sterilized by filtration with a 0.22 μm filter membrane, and diluted with serum-free culture medium to the required concentration when used.
[0140] Preparation of dichlorofluorescein diacetate (DCFH-DA) probe solution: dilute at a ratio of 0.375 μL DCFH-DA: 1 mL PBS.
[0141] HaCaT cells in the logarithmic growth phase were cultured at 1×10 5 The cells were inoculated at a density of 100 cells / mL in a 12-well culture plate, with 1 mL of cell suspension in each well, and cultured in a carbon dioxide incubator at 37°C and 5% CO2 for 24 hours.
[0142] The lid of the culture plate was removed and covered with plastic wrap. UVA was irradiated at an intensity of 2000μW / cm2 for 30 min, and UVB was irradiated at an intensity of 700μW / cm2 for 3 min. The normal control group was covered with aluminum foil and not irradiated.
[0143] After irradiation, discard the old culture medium, add sample solution to the experimental group, and add serum-free culture medium to the model group and normal control group, 1 mL per well, and continue to culture for 24 hours. After the culture is completed, discard all the culture medium and wash twice with PBS. Add 1.5 mL of DCFH-DA solution to each well, put it in the cell culture incubator and continue to incubate for 30 minutes, and mix it every 5 minutes to allow the probe to fully bind. Discard the probe, wash twice with preheated serum-free culture medium, add 1 ml of serum-free culture medium to each well and incubate at 37°C for 10 minutes. After washing once with PBS, trypsinize the cells, wash twice with PBS, resuspend in 300 μL PBS, and detect with flow cytometer (filter the cells with a 100-mesh filter before loading), FITC-A channel, and collect 10,000 cells for each sample.
[0144] HaCaT cells in the logarithmic growth phase were cultured at 1×10 5 The cells were inoculated at a density of 100 cells / mL in a 12-well culture plate, with 1 mL of cell suspension in each well, and cultured in a carbon dioxide incubator at 37°C and 5% CO2 for 24 hours.
[0145] The old culture medium was discarded, and the sample solution was added to the experimental group, and serum-free culture medium was added to the model group and the normal control group, with 1 mL per well. The culture was continued for 24 hours before irradiation.
[0146] Remove the lid of the culture plate and cover with plastic wrap. Irradiate with UVA at an intensity of 2000μW / cm2 for 30min and UVB at an intensity of 700μW / cm2 for 3min. The normal control group is covered with aluminum foil and not irradiated. After irradiation, discard the old culture medium, add serum-free culture medium, and continue to culture for 3h. After the culture is completed, discard all the culture medium and wash twice with PBS. Add 1.5mL DCFH-DA to each well and continue to incubate in the cell culture incubator for 30min. Mix every 5min to allow the probe to fully bind. Discard the probe, wash twice with preheated serum-free culture medium, add 1ml serum-free culture medium to each well and incubate at 37℃ for 10min. After washing once with PBS, trypsinize the cells, wash twice with PBS, resuspend in 300μL PBS, and detect with flow cytometer (filter the cells with a 100-mesh filter before loading), FL1-H channel, and collect 10,000 cells for each sample.
[0147] ROS inhibition rate = (1-(average fluorescence intensity of experimental group / average fluorescence intensity of model group)) × 100%
[0148] The results are shown in Table 8. Compared with the control group, the ROS content in the model group was significantly increased, proving that the UV damage model was successfully established. In terms of UV damage protection, compared with the control group, the ROS inhibition rate of the chondroitin oligosaccharide test group was 37.62%, and the ROS inhibition rate of the hyaluronic acid oligosaccharide test group was 38.64%, which shows that both chondroitin oligosaccharides and hyaluronic acid oligosaccharides have a scavenging effect on the generation of intracellular ROS induced by ultraviolet rays, and have a certain protective effect on UV damage, and the two have comparable effects.
[0149] In terms of UV damage repair, chondroitin oligosaccharides have a slight scavenging effect on UV-induced ROS, while hyaluronic acid oligosaccharides have almost no such effect.
[0150] Table 8 Samples and their effects on the content of reactive oxygen free radicals (ROS)
[0151]
[0152] ## indicates p<0.01 compared with the Control group; * indicates p<0.05 compared with the model group; ** indicates p<0.01 compared with the model group (t test); “—” indicates not applicable.
[0153] 5. Evaluation of anti-inflammatory efficacy
[0154] Mouse macrophage cell line was used as model cells. Macrophages were stimulated with LPS to produce excessive inflammatory molecules. The samples were used for treatment. The expression of inflammatory factors in the culture supernatant was quantitatively detected to examine the inhibitory effect of the samples on the release of inflammatory factors.
[0155] Use serum-free 1640 culture medium to prepare a mother solution with a concentration of 500,000 units / mL, filter it through a 0.22 μm filter membrane for sterilization, store it in a -20°C refrigerator, and dilute it to a working solution of 40,000 units / mL before use.
[0156] The sample solution was prepared with LPS solution and sterilized by filtration with a 0.22 μm filter membrane.
[0157] Raw264.7 mouse macrophages in logarithmic growth phase were obtained and 5×10 4 The cells were inoculated in a 24-well plate at a density of cells / mL, 1 mL per well. The culture system was RPMI1640 medium supplemented with 10% fetal bovine serum. The inoculated cells were placed in a carbon dioxide incubator at 37°C and 5% CO2 for routine culture for 24 hours.
[0158] After routine culture for 24 h, the old culture medium was discarded, and the experimental group was replaced with 1 mL of sample. The normal control group (control) was added with an equal amount of serum-free culture medium and 40,000 units of LPS as a model control, and culture was continued for 24 h.
[0159] The cell supernatant was collected and centrifuged, and the TNF-α content was determined according to the kit instructions.
[0160] The results are shown in Table 9. Compared with the Control, LPS promotes macrophages to produce more TNF-α. Chondroitin oligosaccharides can inhibit the secretion of intracellular TNF-α induced by LPS, but the inhibitory effect is not as strong as that of hyaluronic acid oligosaccharides. This shows that chondroitin oligosaccharides have a certain anti-inflammatory effect, but the effect is not as strong as that of hyaluronic acid oligosaccharides.
[0161] Table 9 Effects of samples on TNF-α production by macrophages
[0162]
[0163] ## indicates p<0.01 compared with the Control group; * indicates p<0.05 compared with the model group; ** indicates p<0.01 compared with the model group (t test).
[0164] 6. Evaluation of the efficacy of promoting collagen production
[0165] Type I collagen is the most abundant structural protein in connective tissues such as the skin. The gene of the human α1(Ⅰ) chain contains 51 exons, so the splicing after gene transcription is very complex. The translated peptide chain is called the pre-α chain, and each end of it has a propeptide without a Gly-XY sequence. The C-terminal propeptides of the three pre-α chains form interchain crosslinks through disulfide bonds, so that the three pre-α chains are "aligned". Then a triple helix structure is formed from the C-terminus to the N-terminus. The propeptide part is non-helical curled. The triple helical collagen molecule with propeptides is called procollagen, which is characterized by a 300nm triple helical domain flanked by globular N and C-terminal propeptides. Specifically, human procollagen Ialpha 1 consists of a signal peptide (aa1-22), a propeptide (aa23-161), a mature chain (aa162-1218) and another propeptide (aa1219-1464). The non-helical propeptide is removed by protease activity at the N and C terminals of procollagen, so that the mature triple helix can self-assemble into collagen fibers, providing tensile strength to tissues. Determination of the content of human procollagen Ialpha1 can directly reflect the amount of type I collagen synthesized by cells.
[0166] Take HFF-1 in logarithmic growth period and take 1×10 5 The cells were inoculated in a 12-well plate at a density of cells / mL, 1 mL per well. The culture system was DMEM culture medium supplemented with 15% fetal bovine serum. The inoculated cells were placed in a carbon dioxide incubator at 37°C and 5% CO2 for routine culture for 24 hours.
[0167] After routine culture for 24 h, the old culture medium was discarded, and the experimental group was replaced with 1 mL of sample, and the normal control group (control) was added with an equal amount of serum-containing culture medium and cultured for another 24 h.
[0168] The cell culture supernatant was collected and the procollagen Iα1 content was determined by referring to the human Pro-Collagen I alpha 1 ELISA kit.
[0169] The results are shown in Table 10. Both chondroitin oligosaccharide and hyaluronic acid oligosaccharide have the effect of promoting the production of procollagen Ialpha 1, and chondroitin oligosaccharide has a better effect in promoting collagen secretion.
[0170] Table 10 Effects of samples on procollagen secretion
[0171]
[0172] * indicates p<0.05 compared with the model group; ** indicates p<0.01 compared with the model group (t test).
[0173] Sequence Listing
[0174] SEQ ID NO.1:
[0175]
[0176] SEQ ID NO. 2:
[0177]
[0178]
[0179] SEQ ID NO.3
[0180]
[0181]
[0182] SEQ ID NO.4:
[0183]
[0184]
[0185] SEQ ID NO.5:
[0186] CCGGAATTCATGAAGACACTACGCGGCTC
[0187] SEQ ID NO.6:
[0188] ATTTGCGGCCGCTCAATGATGATGATGGTGGTGATGAAGGGTGAACTTCTT Sequence Listing <110> Bloomage Biotech Co., Ltd. <120> A method for preparing chondroitin oligosaccharides by enzymatic method and chondroitin oligosaccharide composition <130> TPE01678 <160> 6 <170> PatentIn version 3.5 <210> 1 <211> 1074 <212> DNA <213> Artificial sequence <220> <223> Artificially synthesized sequences <400> 1 atgatcccac ccgcacgtga ctcgcttatg tttgtctttg cgactgcggt aatcgctagt 60 ttttcggta gcgcaagac actacgcggc tctccccac agcaatcga cgtatactgg 120 aatgtgccaa ctttcatgtg tcacaagcac ggtatgaaat ttgagagct gaagatttc 180 ggtatacacc agaacgcaat ggatatgttt cgcggcgaag aaattgcgat tctttatgac 240 cctggcatgt ttcccgccct tctagtagat aagatggat acgtcactaa acggaacggt 300 ggggtgccgc agagggaa cctcaggaa catttagaaa cctttagaaa gcatctgacg 360 acacaaatttc cggacgagag ctttagcggg ataggaatca tagacttga gagttgaga 420 ccgattttca ggcagaactg ggcgtcactc gagccctata aaactttgtc cataaagttg 480 gagagggaa aacacccatt ttggtcggag gcagctgtga agaaggaggc caacgtcga 540 ttcgagaat ccggcgaat atttatggag gaaaccctca aaatggccaa aaactaaga 600 ccgaaagcaa agtggggcta ttatgggtat ccccactgtt tcaatcaac ccctggacag 660 cagtcggttc actgcaatcg gcaacgatg atggaaatg acggtatgag ttggctgttt 720 acacctcgaag acgttcatgc tcccagcgtt tacctacgat tggaatca ggaggatgac 780 cggccttcat tcgtgaaagg ccggggtttcc gaggccttaa ggttagccgc taaatcgtct tcaaaacaac gtatcctacc ttactactgg ttcatttatc aggataagaa ggatgagttc 960. ttacggaa aggatacaca aaacactata aattgatcg ctaatctggg atctaatggt ttcataattt ggggatctag tgacgatgtc aacacggac gcaaatgcaa ggatttacag caatacgtaa aggaagtctt gggcccagcg attaagaagt tcacccttca ttga <210> 2 <211> 357 <212> PRT <213> The snowstorm <220> <223> A snowflake snowflake <400> 2 Met Ile Pro Pro Ala Arg Asp The Best Of Met Ile Pro Pro Ala Thr Ala 1 5 10 15 Val Ile Ala Ser Phe Phe Gly Ser Free Mp3 Download 20 25 30 Pro Gln Gln Phe Asp Val Tyr Trp Asn Val Pro Thr Phe Met Cys His 35 40 45 Light His Gly Met Light Phe Glu Glu Leu Light Asp Phe Gly Ile His Gln 50 55 60 Asn Ala Met Asp Met Phe Arg Gly Glu Glu Ile Ala Ile Leu Tyr Asp 65 70 75 80 Pro Gly Met Phe Pro Ala Leu Leu Val Asp Lys Asp Gly Tyr Val Thr 85 90 95 Lys Arg Asn Gly Gly Val Pro Gln Glu Gly Asn Leu Lys Glu His Leu 100 105 110 Glu Thr Phe Arg Lys His Leu Thr Thr Gln Ile Pro Asp Glu Ser Phe 115 120 125 Ser Gly Ile Gly Ile Ile Asp Phe Glu Ser Trp Arg Pro Ile Phe Arg 130 135 140 Gln Asn Trp Ala Ser Leu Glu Pro Tyr Lys Thr Leu Ser Ile Lys Leu 145 150 155 160 Glu Arg Glu Lys His Pro Phe Trp Ser Glu Ala Ala Val Lys Lys Glu 165 170 175 Ala Lys Arg Arg Phe Glu Lys Ser Gly Arg Ile Phe Met Glu Glu Thr 180 185 190 Leu Lys Met Ala Lys Lys Leu Arg Pro Lys Ala Lys Trp Gly Tyr Tyr 195 200 205 Gly Tyr Pro His Cys Phe Asn Gln Thr Pro Gly Gln Gln Ser Val His 210 215 220 Cys Asn Arg Gln Thr Met Met Glu Asn Asp Gly Met Ser Trp Leu Phe 225 230 235 240 Thr Leu Glu Asp Val His Ala Pro Ser Val Tyr Leu Arg Leu Glu Ile 245 250 255 Lys Glu Asp Asp Arg Pro Ser Phe Val Lys Gly Arg Val Ser Glu Ala 260 265 270 Leu Arg Leu Ala Ala Lys Ser Ser Ser Lys Gln Arg Ile Leu Pro Tyr 275 280 285 Tyr Trp Phe Ile Tyr Gln Asp Lys Lys Asp Glu Phe Leu Thr Glu Lys 290 295 300 Asp Thr Gln Asn Thr Ile Asn Met Ile Ala Asn Leu Gly Ser Asn Gly 305 310 315 320 Phe Ile Ile Trp Gly Ser Ser Asp Asp Val Asn Thr Glu Arg Lys Cys 325 330 335 Lys Asp Leu Gln Gln Tyr Val Lys Glu Val Leu Gly Pro Ala Ile Lys 340 345 350 Lys Phe Thr Leu His 355 <210> 3 <211> 1020 <212> DNA <213> artificial sequence <220> <223> Artificial synthesis <400> 3 atgaagacac tacgcggctc ttccccag caatcgacg tatactggaa tgtgccaact 60 ttcatgtgtc acagcacgg tatgaattt gagagctga aagatttcgg tatacaccag 120 aacgcaatgg atatgtttcg cggcgaagaa attgcgattc ttatgacc tggcatgttt 180 cccgcccttc tagtagataa agatggatac gtcactaac ggaacggtgg ggtgccgcaa 240 gaggggaacc tcaggaaca tttagaaagc atctgacgac acaattccg 300 gacgagagct ttagcgggat aggaatcata gacttgaga gttggagacc gattttcagg 360 cagaactggg cgtcactcga gcccttaaa actttgtcca taaagttgga gagggaaaaa 420 cacccatttt gtcggaggc agctgtgaag aaggaggcca aacgtcgatt cgagaatcc 480 gggcgaatat ttatggagga aaccctcaa atggccaaa actaagacc gaagcaag 540 tggggtatt atgggtatcc ccactgtttc aatcaaaccc ctggacagca gtcggttcac 600 tgcaatcggc aaacgatgat ggaaatgac ggtagagtt ggctgtttac actcgaagac 660 gttcatgctc ccagcgttta cctacgattg gaatcagg aggatgaccg gccttcattc 720 gtgaaaggcc gggtttccga ggccttaagg ttagccgcta aatcgtcttc aaaacaacgt 780 atcctacctt actactggtt catttatcag gataagaagg atgagttctt aacggaaaag 840 gatacacaaa acactataaa tatgatcgct aatctgggat ctaatggttt cataatttgg 900 ggatctagtg acgatgtcaa cacggaacgc aaatgcaagg atttacagca atacgtaaag 960 gaagtcttgg gcccagcgat taagaagttc acccttcatc accaccatca tcatcattga 1020 <210> 4 <211> 339 <212> PRT <213> Artificial Sequence <220> <223> Artificially synthesized sequence <400> 4 Met Lys Thr Leu Arg Gly Ser Ser Pro Gln Gln Phe Asp Val Tyr Trp 1 5 10 15 Asn Val Pro Thr Phe Met Cys His Lys His Gly Met Lys Phe Glu Glu 20 25 30 Leu Lys Asp Phe Gly Ile His Gln Asn Ala Met Asp Met Phe Arg Gly 35 40 45 Glu Glu Ile Ala Ile Leu Tyr Asp Pro Gly Met Phe Pro Ala Leu Leu 50 55 60 Val Asp Lys Asp Gly Tyr Val Thr Lys Arg Asn Gly Gly Val Pro Gln 65 70 75 80 Glu Gly Asn Leu Lys Glu His Leu Glu Thr Phe Arg Lys His Leu Thr 85 90 95 Thr Gln Ile Pro Asp Glu Ser Phe Ser Gly Ile Gly Ile Ile Asp Phe 100 105 110 Glu Ser Trp Arg Pro Ile Phe Arg Gln Asn Trp Ala Ser Leu Glu Pro 115 120 125 Tyr Lys Thr Leu Ser Ile Lys Leu Glu Arg Glu Lys His Pro Phe Trp 130 135 140 Ser Glu Ala Ala Val Lys Lys Glu Ala Lys Arg Arg Phe Glu Lys Ser 145 150 155 160 Gly Arg Ile Phe Met Glu Glu Thr Leu Lys Met Ala Lys Lys Leu Arg 165 170 175 Pro Lys Ala Lys Trp Gly Tyr Tyr Gly Tyr Pro His Cys Phe Asn Gln 180 185 190 Thr Pro Gly Gln Gln Ser Val His Cys Asn Arg Gln Thr Met Met Glu 195 200 205 Asn Asp Gly Met Ser Trp Leu Phe Thr Leu Glu Asp Val His Ala Pro 210 215 220 Ser Val Tyr Leu Arg Leu Glu Ile Lys Glu Asp Asp Arg Pro Ser Phe 225 230 235 240 Val Lys Gly Arg Val Ser Glu Ala Leu Arg Leu Ala Ala Lys Ser Ser 245 250 255 Ser Lys Gln Arg Ile Leu Pro Tyr Tyr Trp Phe Ile Tyr Gln Asp Lys 260 265 270 Lys Asp Glu Phe Leu Thr Glu Lys Asp Thr Gln Asn Thr Ile Asn Met 275 280 285 Ile Ala Asn Leu Gly Ser Asn Gly Phe Ile Ile Trp Gly Ser Ser Asp 290 295 300 Asp Val Asn Thr Glu Arg Lys Cys Lys Asp Leu Gln Gln Tyr Val Lys 305 310 315 320 Glu Val Leu Gly Pro Ala Ile Lys Lys Phe Thr Leu His His His His 325 330 335 His His His <210> 5 <211> 29 <212> DNA <213> Artificial sequence <220> <223> Synthetic sequence <400> 5 ccggaattca tgaagacact acgcggctc 29 <210> 6 <211> 51 <212> DNA <213> Artificial sequence <220> <223> Artificially synthesized sequences <400> 6 atttgcggcc gctcaatgat gatgatggtg gtgatgaagg gtgaacttct t 51
Claims
1. A method for preparing chondroitin oligosaccharides by enzymatic method, characterized in that: The method comprises the following steps: Add hyaluronidase to the chondroitin solution to react. The reaction solution is free of impurities to obtain chondroitin oligosaccharides. The nucleotide sequence of the hyaluronidase is shown in SEQ ID NO.
3.
2. The method according to claim 1, characterized in that In the reaction system consisting of the hyaluronidase and the chondroitin solution, the concentration of chondroitin is 5-20 g / L.
3. The method according to claim 1, characterized in that The weight average molecular weight of chondroitin is 2-3×10 5 Da.
4. The method according to claim 1, characterized in that In the reaction system consisting of the hyaluronidase and the chondroitin solution, the concentration of the hyaluronidase is 2×10 3 -1×10 5 U / mL.
5. The method according to claim 1, characterized in that The ratio of the hyaluronidase to the chondroitin is 1000-3000 U / mg.
6. The method according to claim 1, characterized in that The reaction temperature is 20-65°C and the reaction time is 0.5-8 h.
7. The method according to claim 1, characterized in that The impurities in the reaction solution are removed by ultrafiltration and nanofiltration.
8. The method according to claim 7, characterized in that Organic membranes with a molecular weight cutoff of 2-3 kDa and a molecular weight cutoff of 300-500 Da were used to remove high molecular weight impurities and low molecular weight impurities.
9. The method according to claim 1, characterized in that: The chondroitin oligosaccharides include chondroitin tetrasaccharide, chondroitin hexasaccharide, chondroitin octasaccharide and chondroitin decasaccharide.
10. The method according to claim 1, characterized in that The molecular weight of the chondroitin oligosaccharide is less than 2000Da.
11. A chondroitin oligosaccharide composition, characterized in that: The chondroitin oligosaccharide composition comprises chondroitin tetrasaccharide, chondroitin hexasaccharide, chondroitin octasaccharide and chondroitin decasaccharide, and the chondroitin oligosaccharide is prepared by the method according to any one of claims 1-10.
12. The composition according to claim 11, characterized in that The molecular weight of the chondroitin oligosaccharide is less than 2000 Da.
13. Use of the composition of claim 11 or 12 in the preparation of products for preventing dryness, repairing dryness, promoting angiogenesis, protecting or repairing ultraviolet damage, anti-inflammatory, or promoting collagen production.
